Prime Medicine, Inc.
PRMENasdaq
$3.13
↓ -2.8%Jul 17 close · end-of-day
Price
1Y↓ -22.5%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$554.3M
Enterprise Value
$418.8M
P/E
—
P/S
—
P/B
7.2
EV/EBITDA
—
PEG
—
FCF Yield
-28.6%
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
-$198.4M
Free Cash Flow (TTM)
-$158.7M
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
-258.6%
ROIC
—
Debt / Equity
—
Net Cash
$135.5M
Return 1Y
-19.7%
Company profile
We are a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, Prime Editors, to address the widest spectrum of diseases by deploying our Prime Editing technology, which we believe is a versatile, precise, efficient and broad gene editing technology. We were incorporated under the laws of the State of Delaware in September 2019 under the name Prime Medicine, Inc. Our principal executive offices are located at 21 Erie Street, Cambridge, MA.
- CEO
- Keith M. Gottesdiener
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Headquarters
- Massachusetts
- Website
- primemedicine.com
Earnings
PRME Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue——
Diluted EPS-$0.28↓ -30.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $5.2M | $0.00 | $0.00 | $0.00 | $3.0M | $4.6M |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$932,000.00 | -$84.5M | -$116.5M | -$204.8M | -$202.5M | -$208.3M |
| Net income | -$3.4M | -$165.4M | -$121.8M | -$198.1M | -$195.9M | -$201.1M |
| Diluted EPS | -$1.91 | -$14.19 | -$4.19 | -$2.18 | -$1.65 | -$1.35 |
| Operating cash flow | -$5.5M | -$34.1M | -$131.8M | -$165.4M | -$122.9M | -$162.6M |
| Free cash flow | -$6.2M | -$38.2M | -$147.9M | -$174.1M | -$130.2M | -$167.1M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | -17.9% | — | — | — | -6787.4% | -4498.1% |
| Net margin | -65.5% | — | — | — | -6566.6% | -4342.4% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $209,000.00 | $2.2M | $1.5M | $1.1M | $1.2M | $838,000.00 | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$55.7M | -$54.2M | -$44.2M | -$52.4M | -$53.4M | -$54.0M | -$48.6M | -$50.7M |
| Net income | -$55.3M | -$52.5M | -$42.3M | -$51.9M | -$52.6M | -$50.6M | -$46.1M | -$49.1M |
| Diluted EPS | -$0.46 | -$0.44 | -$0.31 | -$0.40 | -$0.41 | -$0.32 | -$0.22 | -$0.28 |
| Operating cash flow | -$45.5M | -$25.9M | $16.2M | -$48.9M | -$41.4M | -$35.0M | -$37.3M | -$42.7M |
| Free cash flow | -$47.4M | -$27.2M | $14.5M | -$51.3M | -$43.0M | -$35.3M | -$37.5M | -$42.9M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | -25948.3% | -2025.7% | -3603.3% | -4787.2% | -4406.0% | -5800.5% | — |
| Net margin | — | -25128.2% | -1936.6% | -3568.8% | -4716.7% | -4129.1% | -5498.7% | — |
Company news
Jul 15, 2026
Jul 8, 2026
- 12d agoGene Editors, Including Powerhouse Beam Therapeutics, Diverge On Legal Battlefinance.yahoo.com
- 12d agoPRME Surges 15% After Winning Arbitration Against Beam — Clears Path To Human Trials For Its Gene-Editing Drugstocktwits.com
- 12d agoPrime Medicine Announces Positive Resolution to Arbitration with Beam Therapeuticsfinance.yahoo.com
- 12d agoPrime wins gene editing dispute; Saol claims latest post-Makary FDA reversalbiopharmadive.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2025-08-01 | ARCH Venture Partners X, LLC | Buy | 3,030,300 | $3.30 | $10.0M | filing |
| 2025-08-01 | NELSEN ROBERT | Buy | 3,030,300 | $3.30 | $10.0M | filing |
| 2025-08-01 | ARCH Venture Partners XII, LLC | Buy | 3,030,300 | $3.30 | $10.0M | filing |
| 2025-08-01 | GV 2021 GP, L.L.C. | Buy | 1,500,000 | $3.30 | $5.0M | filing |
| 2025-06-30 | Liu David R. | Buy | 21,000 | $2.52 | $52,829.70 | filing |
| 2025-06-23 | Liu David R. | Buy | 21,000 | $2.16 | $45,402.00 | filing |
| 2025-06-16 | Liu David R. | Buy | 21,000 | $1.49 | $31,195.50 | filing |
Latest 7 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.